BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 341 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 341 shares of the company’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $300.00, for a total transaction of $102,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, February 4th, Chan Henry Lee sold 1,660 shares of BeOne Medicines stock. The stock was sold at an average price of $349.52, for a total transaction of $580,203.20.
• On Wednesday, January 7th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The stock was sold at an average price of $331.76, for a total value of $220,288.64.

BeOne Medicines Trading Down 0.4%

Shares of BeOne Medicines stock opened at $284.05 on Friday. The stock has a market capitalization of $31.15 billion, a P/E ratio of 112.72 and a beta of 0.53. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $196.45 and a 52-week high of $385.22. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.08 and a current ratio of 3.41. The stock’s 50-day simple moving average is $334.52 and its 200 day simple moving average is $329.55.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Thursday, February 26th. The company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($1.02). BeOne Medicines had a return on equity of 10.70% and a net margin of 5.37%.The company had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. As a group, research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on ONC shares. Jefferies Financial Group reissued a “buy” rating and issued a $420.00 target price on shares of BeOne Medicines in a research note on Monday, November 17th. Truist Financial upped their price objective on BeOne Medicines from $400.00 to $412.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Barclays increased their price objective on BeOne Medicines from $394.00 to $405.00 and gave the company an “overweight” rating in a research report on Friday, February 27th. Wall Street Zen downgraded BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Royal Bank Of Canada upped their target price on BeOne Medicines from $417.00 to $425.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $401.00.

Institutional Trading of BeOne Medicines

Several large investors have recently modified their holdings of ONC. Corient Private Wealth LLC raised its holdings in shares of BeOne Medicines by 26.5% during the fourth quarter. Corient Private Wealth LLC now owns 1,069 shares of the company’s stock valued at $325,000 after acquiring an additional 224 shares in the last quarter. Compound Planning Inc. purchased a new position in BeOne Medicines during the 4th quarter valued at $223,000. Invesco Ltd. raised its holdings in BeOne Medicines by 1,008.6% in the 4th quarter. Invesco Ltd. now owns 14,123 shares of the company’s stock worth $4,291,000 after purchasing an additional 12,849 shares in the last quarter. Vident Advisory LLC raised its holdings in BeOne Medicines by 20.4% in the 4th quarter. Vident Advisory LLC now owns 2,052 shares of the company’s stock worth $623,000 after purchasing an additional 347 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of BeOne Medicines in the 4th quarter worth about $2,912,000. 48.55% of the stock is owned by institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.